We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

T2 Biosystems Inc (TTOO) USD0.001

Sell:$5.50 Buy:$5.72 Change: $0.52 (10.46%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Change: $0.52 (10.46%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Change: $0.52 (10.46%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Contact details

101 Hartwell Ave
United States
+1 (781) 4571200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$75.75 million
Shares in issue:
15.37 million
United States
US dollar

Key personnel

  • John Sperzel
    Chairman of the Board, President, Chief Executive Officer
  • John Sprague
    Chief Financial Officer
  • Michael Gibbs
    Senior Vice President, General Counsel
  • Roger Smith
    Senior Vice President of Science Research and Development
  • Brett Giffin
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.